UK markets closed

Bone Therapeutics SA (BNZPF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
4.20000.0000 (0.00%)
At close: 11:30AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close4.2000
Open4.2000
BidN/A x N/A
AskN/A x N/A
Day's range4.2000 - 4.2000
52-week range4.2000 - 4.2600
Volume240
Avg. volume0
Market cap43.46M
Beta (5Y monthly)0.22
PE ratio (TTM)N/A
EPS (TTM)-0.8060
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Bone Therapeutics SA: Information on the total number of voting rights and shares

    REGULATED INFORMATION Mont-Saint-Guibert, Belgium, 30 June 2022, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces an increase in the total number of voting rights and shares as a result of the issuance of new shares following the conversion of convertible bonds (CBs) issued on 9 June 2022. The following information is published in accordance with Article 15 of the Belgian

  • Globe Newswire

    Bone Therapeutics to host Extraordinary General Meeting on 13 July 2022

    REGULATED INFORMATION Preliminary documents for the Extraordinary General Meeting have been made available on company’s website Mont-Saint-Guibert, Belgium, 13 June 2022, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics, invites its shareholders and the holders of registered subscription rights and registered convertible bonds of the Company to the extraordinary general meeting to be held on Wednesday 13 Jul

  • Globe Newswire

    Bone Therapeutics Provides First Quarter 2022 Business Update

    REGULATED INFORMATION Mont-Saint-Guibert, Belgium, 1 June 2022, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces its business update for the first quarter, ended 31 March 2022. “Bone Therapeutics is now concentrating fully on the development of our allogeneic cell therapy product, ALLOB. We remain on target for delivery of topline results for the Phase IIb study ALLOB, in